Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

Joseph I Clark; Brendan Curti; Elizabeth J Davis; Howard Kaufman; Asim Amin; Ajjai Alva; Theodore F Logan; Ralph Hauke; Gerald P Miletello; Ulka Vaishampayan; Douglas B Johnson; Richard L White; Peter H Wiernik; Janice P Dutcher

doi:10.1136/jim-2020-001650

Open Access

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, Janice P Dutcher

DOI: 10.1136/jim-2020-001650 Published 1 April 2021

Joseph I Clark

1 Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Brendan Curti

2 Earle A. Chiles Research Institute, Providence Medical Center, Portland, Oregon, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elizabeth J Davis

3 Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Howard Kaufman

4 Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Asim Amin

5 Medicine, Levine Cancer Institute, Charlotte, North Carolina, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ajjai Alva

6 Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Theodore F Logan

7 Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ralph Hauke

8 Medicine, Nebraska Cancer Specialists, Omaha, Nebraska, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gerald P Miletello

9 Medicine, Hematology/Oncology Clinic, Baton Rouge, Louisiana, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ulka Vaishampayan

10 Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Douglas B Johnson

3 Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Richard L White

5 Medicine, Levine Cancer Institute, Charlotte, North Carolina, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter H Wiernik

11 Medicine, New York Medical College, Valhalla, New York, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Peter H Wiernik

Janice P Dutcher

11 Medicine, New York Medical College, Valhalla, New York, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Janice P Dutcher

Article
Figures & Data
eLetters
Info & Metrics
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

No eLetters have been published for this article.

PreviousNext

Vol 69 Issue 4 Table of Contents

Journal of Investigative Medicine: 69 (4)

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
AFMR Highlights
Front Matter (PDF)

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

Message Subject (Your Name) has sent you a message from JIM

Message Body (Your Name) thought you would like to see the JIM web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.